癌症生物製药市场－全球产业规模、份额、趋势、机会及预测（按产品、应用、最终用户、地区和竞争格局划分，2021-2031年）

全球癌症生物製剂市场预计将从 2025 年的 1,008.6 亿美元成长到 2031 年的 1,528.1 亿美元，复合年增长率为 7.17%。

肿瘤生物製剂是生物来源的治疗药物，例如单株抗体和疫苗，旨在透过靶向特定免疫路径或癌细胞来治疗恶性肿瘤。这项市场成长的主要驱动力是全球对精准医疗日益增长的需求，以及为确保治疗创新产品线稳定而对肿瘤研究的大量资金投入。这些结构性因素代表临床治疗标准的根本转变，而非昙花一现的趋势。根据欧洲製药工业协会联合会（EFPIA）预测，到2024年，以研发为基础的製药业将在欧洲的研发领域投入约550亿欧元，这充分体现了推动该领域发展的持续资金投入。

儘管市场成长势头强劲，但由于生物製药生产和研发成本高昂，该市场仍面临许多挑战。这种经济负担造成了复杂的报销壁垒，并迫使企业采取高定价策略，从而限制了病患的用药机会，尤其是在对成本高度敏感的医疗体系中。这些经济壁垒有效地限制了发展中地区的潜在市场，并对这些治疗方法的全球推广构成了重大障碍。

市场驱动因素

全球各类癌症发生率的不断上升，正成为市场扩张的主要催化剂，也因此亟需广泛应用先进的生物疗法。随着人口老化和环境因素导致肿瘤疾病负担日益加重，医疗系统越来越依赖生物製药，因为生物製剂具有标靶特异性机制，与全身化疗显着不同。患者数量的激增与单株抗体和免疫疗法需求的增长直接相关，促使医疗机构将这些治疗方法纳入标准通讯协定。根据美国癌症协会发布的《2024年癌症事实与数据》（2024年1月），预计美国2024年新增癌症病例将首次突破200万例，这一里程碑事件凸显了有效生物干预措施的必要性。

随着需求的增长，生物製药研发的快速进展以及随之而来的监管核准激增，正在推动该领域的翻天覆地变化。生物製药开发商优先设计具有卓越疗效和安全性特征的复杂分子，从而开启了新型药物活性化的时期。这种监管势头确保了研究突破能够迅速转化为实际治疗方法。根据美国食品药物管理局（FDA）于2024年1月发布的《2023年新药核准情况》，该机构核准了55种新型疗法，核准率的显着提高促进了药物更快进入市场。这些核准疗法的商业性成功显而易见：据默克公司称，其生技药品Keytruda在2023年全年的全球销售额增长了19%，达到250亿美元。

市场挑战

生物製药生产和研发的高昂成本是限制全球肿瘤生物製药市场成长的主要障碍。与传统小分子药物不同，肿瘤生物製药需要使用活细胞株进行高度复杂的生产工艺，这需要大量的前期投资和精密的配套设施。这种沉重的经济负担迫使生产商采取高定价策略来回收研发投入。因此，高昂的价格在医疗体系内造成了巨大的摩擦，导致严格的报销审查和有限的药品目录覆盖。

这种经济压力直接阻碍了市场扩张，限制了患者获得这些先进疗法的机会，尤其是在对成本敏感的地区。系统性的动态进一步加剧了定价的复杂性，使患者更难负担这些药物。美国药品研究与製造商协会 (PhRMA) 2024 年的一份报告发现，医院门诊机构的癌症药物价格比医生诊所高出 1.3 到 4.3 倍。这些价格差异进一步加剧了上述报销障碍，由于支付方和患者都在努力应对不断上涨的医疗成本，实际上缩小了潜在市场。

市场趋势

抗体药物复合体(ADC) 产品线的快速扩张标誌着该领域的重大变革，其发展方向正从传统的单株抗体转向能够将细胞毒性有效载荷直接递送至癌细胞的修饰型 ADC。这一趋势的特点是，各公司正集中投资于生产能力建设，以支持这些疗法所需的复杂偶联製程。与传统化疗相比，ADC 具有更高的疗效和更低的全身毒性。主要企业正致力于保障其供应链，以确保这些标靶药物的产能扩张。 2024 年 5 月，Astra Zeneca承诺投资 15 亿美元在新加坡建造一座专用生产设施，以增强其 ADC 产品组合的全球供应，体现了该公司对该治疗方法的高度战略重视。

同时，人工智慧在生物製药研发中的应用正从根本上改变蛋白质工程和标靶辨识的效率。製药开发商正越来越多地与科技公司建立高价值合作关係，利用生成模型预测蛋白质结构并优化结合亲和性，从而有效缩短新型生物製药进入临床试验的时间。这些合作使得探索传统筛检方法无法触及的广大生物学领域成为可能。 2024年1月，Isomorphic Labs宣布与礼来公司达成一项价值高达17亿美元的多标靶合作，旨在利用数位生物学方法发现新型态疗法。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球癌症生物製药市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 副产品（单株抗体、以细胞激素为基础的免疫疗法、癌症疫苗、CAR-T细胞疗法、免疫查核点抑制剂）
  • 依应用领域（非小细胞肺癌、摄护腺癌、乳癌、急性骨髓性白血病、淋巴瘤、其他）
  • 按最终使用者（医院/诊所、门诊护理中心、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美生物製药市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲癌症生物製药市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区生物製药市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲生物製药市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲癌症生物製药市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球生物製药市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Roche Holding AG
• Novartis AG
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Amgen Inc.
• Johnson & Johnson
• Pfizer Inc.
• AstraZeneca plc
• Eli Lilly and Company
• AbbVie Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Cancer Biologics Market is projected to grow from USD 100.86 Billion in 2025 to USD 152.81 Billion by 2031, expanding at a CAGR of 7.17%. Cancer biologics are therapeutic agents derived from living organisms, such as monoclonal antibodies and vaccines, engineered to treat malignancies by targeting specific immune pathways or tumor cells. This market growth is primarily supported by the increasing global demand for precision medicine and substantial capital allocation toward oncology research, ensuring a steady pipeline of therapeutic innovations. These structural drivers represent a fundamental shift in clinical standards of care, rather than temporary trends. According to the European Federation of Pharmaceutical Industries and Associations, the research-based pharmaceutical industry invested an estimated €55 billion in R&D in Europe in 2024, demonstrating the sustained financial commitment fueling this sector.

Despite this strong growth trajectory, the market faces a significant challenge due to the prohibitive costs associated with biopharmaceutical manufacturing and development. This financial burden necessitates high pricing strategies that create complex reimbursement hurdles and restrict patient access, particularly in cost-sensitive healthcare systems. Such economic barriers effectively limit the addressable market in developing regions and pose a substantial impediment to the global expansion of these therapies.

Market Driver

The rising global incidence of various cancer types acts as the primary catalyst for market expansion, necessitating the widespread adoption of advanced biological therapies. As the burden of oncological diseases intensifies due to aging populations and environmental factors, healthcare systems are increasingly relying on biologics for their target-specific mechanisms, which differ significantly from systemic chemotherapy. This surge in patient volume directly correlates with a higher demand for monoclonal antibodies and immunotherapies, compelling providers to integrate these treatments into standard protocols. According to the American Cancer Society's 'Cancer Facts & Figures 2024' (January 2024), the United States is projected to witness over 2 million new cancer cases in 2024 for the first time, a milestone that highlights the critical need for effective biological interventions.

Parallel to rising demand, the rapid advancement in biological drug development and the subsequent surge in regulatory approvals are structurally reshaping the sector. Biopharmaceutical developers are prioritizing the engineering of complex molecules that offer superior efficacy and safety profiles, leading to a prolific period of commercialization for novel agents. This regulatory momentum ensures that breakthroughs in research translate quickly into available treatments. According to the U.S. Food and Drug Administration's 'Novel Drug Approvals for 2023' (January 2024), the agency approved 55 novel therapeutics, marking a significant increase in approval rates that facilitates faster market entry. The substantial commercial viability of these approved therapies is evident; according to Merck & Co. in 2024, worldwide sales for the oncology biologic Keytruda grew 19% to $25.0 billion in the full year of 2023.

Market Challenge

The prohibitive costs associated with biopharmaceutical manufacturing and development constitute a primary impediment to the growth of the Global Cancer Biologics Market. Unlike traditional small-molecule drugs, cancer biologics require highly complex production processes involving living cell lines, which necessitates substantial upfront capital and sophisticated infrastructure. This intense financial burden forces manufacturers to implement high pricing strategies to recoup research and development investments. Consequently, these elevated price points create significant friction within healthcare systems, leading to rigorous reimbursement scrutiny and restricted formulary inclusion.

This economic pressure directly hampers market expansion by limiting patient access to these advanced therapies, particularly in cost-sensitive regions. The pricing dynamics are further complicated by systemic markups that exacerbate the affordability crisis. According to the Pharmaceutical Research and Manufacturers of America in 2024, hospital outpatient facilities charged 1.3 to 4.3 times more than physician offices for cancer medicines. Such disparities in pricing structure intensify the reimbursement hurdles mentioned earlier, effectively shrinking the addressable market as payers and patients struggle to absorb the escalating costs of care.

Market Trends

The rapid expansion of Antibody-Drug Conjugate (ADC) pipelines represents a structural pivot in the sector, moving beyond standard monoclonal antibodies toward armed constructs that deliver cytotoxic payloads directly to tumor cells. This trend is characterized by intense investment in manufacturing capabilities to support the complex conjugation processes required for these therapeutics, which offer higher potency with reduced systemic toxicity compared to traditional chemotherapy. Major industry players are securing their supply chains to ensure the scalability of these targeted agents; according to AstraZeneca in May 2024, the company announced a $1.5 billion capital commitment to construct a facility in Singapore specifically designed to enhance the global supply of its ADC portfolio, reflecting the high strategic priority placed on this modality.

Concurrently, the integration of artificial intelligence into biologic drug discovery is fundamentally altering the efficiency of protein engineering and target identification. Pharmaceutical developers are increasingly forming high-value partnerships with technology firms to utilize generative models that predict protein structures and optimize binding affinities, effectively compressing the timeline for bringing novel biologics to clinical trials. These collaborations enable the exploration of vast biological spaces that were previously inaccessible through conventional screening methods. According to Isomorphic Labs in January 2024, the company established a multi-target collaboration with Eli Lilly valued at up to $1.7 billion to apply digital biology approaches for the discovery of new therapeutic agents.

Key Market Players

• Roche Holding AG
• Novartis AG
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Amgen Inc.
• Johnson & Johnson
• Pfizer Inc.
• AstraZeneca plc
• Eli Lilly and Company
• AbbVie Inc

Report Scope

In this report, the Global Cancer Biologics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cancer Biologics Market, By Product

• Monoclonal Antibodies
• Cytokine-Based Immunotherapy
• Cancer Vaccines
• CAR-T Cell Therapy
• Immune Checkpoint Inhibitors

Cancer Biologics Market, By Application

• Non-small Cell Lung Cancer
• Prostate Cancer
• Breast Cancer
• Acute Myeloid Leukemia
• Lymphoma
• Others

Cancer Biologics Market, By End User

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Cancer Biologics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cancer Biologics Market.

Available Customizations:

Global Cancer Biologics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cancer Biologics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Monoclonal Antibodies, Cytokine-Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy, Immune Checkpoint Inhibitors)
  • 5.2.2. By Application (Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Others)
  • 5.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Cancer Biologics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cancer Biologics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Cancer Biologics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Cancer Biologics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Cancer Biologics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cancer Biologics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Cancer Biologics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Cancer Biologics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Cancer Biologics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Cancer Biologics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Cancer Biologics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cancer Biologics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Cancer Biologics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Cancer Biologics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Cancer Biologics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Cancer Biologics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Cancer Biologics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Cancer Biologics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Cancer Biologics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Cancer Biologics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Cancer Biologics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cancer Biologics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Cancer Biologics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Cancer Biologics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cancer Biologics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Roche Holding AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Novartis AG
• 15.3. Merck & Co., Inc.
• 15.4. Bristol-Myers Squibb Company
• 15.5. Amgen Inc.
• 15.6. Johnson & Johnson
• 15.7. Pfizer Inc.
• 15.8. AstraZeneca plc
• 15.9. Eli Lilly and Company
• 15.10. AbbVie Inc

16. Strategic Recommendations

17. About Us & Disclaimer